Aktie A3DGG2 THERALINK TECHNOLOGIES, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Theralink Technologies, Inc.

Aktien

A3DGG2

US88339Q1094

THER

Markt geschlossen - OTC Markets
Andere Börsenplätze
 18:20:04 17.05.2024 		% 5 Tage % 1. Jan.
0,0007 USD +16,67 % Intraday Chart für Theralink Technologies, Inc. +16,67 % -53,33 %
06.05. Theralink Technologies, Inc. (OTCPK:THER) hat die Übernahme von IMAC Holdings, Inc. (NasdaqCM:BACK) in einer Reverse-Merger-Transaktion abgesagt. CI
20.02. Theralink Technologies, Inc. meldet Ergebnis für das erste Quartal bis zum 31. Dezember 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Theralink Technologies, Inc. cancelled the acquisition of IMAC Holdings, Inc. in a reverse merger transaction.
Theralink Technologies : Accelaration/Increase of Financial Obligation - Form 8-K
Theralink Technologies, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
Theralink Technologies, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates
Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4
Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board
Theralink Technologies, Inc. Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute?s Molecular Tumor Board
Four Penny Stocks That Might Move On News (EPAZ, THER, SDNR, HNRC)
Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023
Theralink Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023
IMAC Holdings, Inc. announced that it has received $4.3 million in funding from Theralink Technologies, Inc. and other investors
Theralink Technologies, Inc. Announces Chief Executive Officer Changes
Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer
Theralink Technologies, Inc. Appoints Mick Ruxin as Chief Medical Officer
Theralink Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023
Theralink Technologies, Inc. entered into a definitive agreement and plan of merger to acquire IMAC Holdings, Inc. for $0.9 million in a reverse merger transaction.
Theralink Technologies, Inc. Announces Termination of Thomas Chilcott as Treasurer and Secretary
Theralink Technologies, Inc. Announces CFO Changes
Theralink Acquires Exclusive Landmark Immunotherapy Patent including Biomarker from Vanderbilt University
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DGG2 Aktie
  4. Nachrichten Theralink Technologies, Inc.
  5. Andere Sprachen